When is the ideal time in the disease course to offer radiotherapy for Dupuytren's disease for the most optimal outcomes?
Do patients still derive significant benefit if radiation is offered outside the proliferative phase?
This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by the Clinical Trials Session Presentation "Toxicities and Quality of Life Following Observation or Radiation Therapy for Dupuytren's Disease in the International DEPART Randomized Trial" by Dr. Jarad Martin.
2 Answers
Mednet Member
Radiation Oncology · Inova Schar Cancer Institute
Answered on
Radiotherapy is most effective when fibroblasts are actively proliferating, i.e., during the cellular or proliferative phase of the disease, when there is a palpable, progressive nodule or cord but no fixed contracture.
Prospective German trials show that treating during this biologically active peri...
Join for free or sign in to see the full answer
Mednet Member
Radiation Oncology · Calvary Mater Hospital
Answered on
This is one of the key questions we are trying to clarify in the DEPART trial. Patients were eligible to be randomized between radiotherapy and observation if <10 degree contracture of a joint, and some evidence of progression over the last 12 months. Final results are expected in 2027.
Given that ra...
Join for free or sign in to see the full answer